Screening and Early Detection

Screening and Early Detection - Early Bird Catches Worm?

• Definition: Identifying unrecognized disease in asymptomatic individuals using tests applied rapidly.
• Primary Aim: Reduce disease-specific mortality & morbidity through early, effective treatment.
• Key Screening Criteria (WHO/Wilson-Jungner):
  • Disease: Important health problem; natural history understood.
  • Test: Suitable, acceptable, valid, reliable.
  • Treatment: Effective at early stage; facilities available.
  • Program: Cost-effective; continuous.
• Pitfalls (Biases):
  • Lead time bias: Apparent ↑survival due to earlier diagnosis.
  • Length time bias: Favors slow-growing, less aggressive cases.
  • Overdiagnosis: Detecting clinically insignificant disease.

⭐ A good screening test must have high sensitivity to detect most cases (true positives) and acceptable specificity (true negatives).

Screening and Early Detection - The Usual Suspects

• Breast Cancer
  • Self-Breast Examination (SBE): Monthly, age 20+.
  • Clinical Breast Examination (CBE): Age 25-39 (q1-3 yrs), age 40+ (annually).
  • Mammography: Age 50-74 (biennially); high-risk earlier/annually.
• Cervical Cancer
  • Pap Smear: Age 21-29 (q3 yrs).
  • Age 30-65: Pap (q3 yrs) OR HPV test (q5 yrs) OR Co-testing (Pap+HPV q5 yrs).
  • Stop >65 yrs if adequate prior negative screening.
• Oral Cancer
  • Visual Inspection (VIOC): Annually for high-risk (tobacco/alcohol users) age 30+.
• Colorectal Cancer (CRC)
  • Age 45/50+: Fecal Occult Blood Test (FOBT)/Fecal Immunochemical Test (FIT) (annually) OR Colonoscopy (q10 yrs).
• Lung Cancer
  • Low-Dose CT (LDCT): Annually, age 50-80 with 20 pack-year smoking history (current/quit <15 yrs).

⭐ Visual Inspection with Acetic Acid (VIA) is a cost-effective cervical cancer screening method for low-resource settings in India, often done by trained health workers.

Screening and Early Detection - Decoding The Data

• Key Metrics for Test Performance:
  • Sensitivity: $TP / (TP + FN)$ (Detects disease)
  • Specificity: $TN / (TN + FP)$ (Confirms absence)
  • Positive Predictive Value (PPV): $TP / (TP + FP)$ (Probability of disease if test +ve; ↑ with prevalence)
  • Negative Predictive Value (NPV): $TN / (TN + FN)$ (Probability of no disease if test -ve; ↓ with prevalence)
• Potential Biases in Screening:
  • Lead-time bias: Apparent survival benefit due to earlier diagnosis, not delayed death.
  • Length-time bias: Preferential detection of slower-growing, less aggressive tumors.
  • Overdiagnosis: Detecting cancers that would not have become clinically significant.
• Program Efficacy: Measured by ↓disease-specific mortality.

⭐ The most crucial outcome for evaluating a screening program's effectiveness is a demonstrable reduction in mortality from the specific cancer, not merely an increase in survival rates or detection rates alone.

Screening and Early Detection - When Family History Calls

• High-risk indicators (FHx):
  • Multiple affected relatives (1st/2nd degree).
  • Early cancer onset (e.g., <50 years).
  • Cancer patterns (breast-ovarian, colon-endometrial).
  • Known family mutation.
• Genetic Counseling & Testing: Assesses risk, guides testing, interprets results. Confirms hereditary syndromes.
  • Key syndromes & genes: HBOC (BRCA1/2), Lynch (MLH1, MSH2, MSH6, PMS2, EPCAM), FAP (APC), Li-Fraumeni (TP53).
• Intensified Surveillance:
  • Earlier screening initiation.
  • ↑ Frequency.
  • Added modalities (e.g., MRI breast).
• Risk-Reduction Strategies:
  • Prophylactic surgery (mastectomy, oophorectomy).
  • Chemoprevention (tamoxifen).

⭐ For BRCA1 carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) is often recommended between ages 35-40, or after childbearing completed anovulatory cycles are not protective against ovarian cancer for BRCA carriers.

High‑Yield Points - ⚡ Biggest Takeaways

• Screening targets asymptomatic individuals; early detection for early symptomatic cases.
• Wilson-Jungner criteria guide screening program suitability.
• Key metrics: Sensitivity, Specificity; PPV varies with prevalence.
• Examples: Mammography (breast, >40-50 yrs), Pap smear (cervical), Colonoscopy/FOBT (colorectal).
• Lead-time bias: Apparent survival ↑ due to earlier diagnosis, not improved outcome.
• Length-time bias: Preferential detection of slow-growing tumors.
• Overdiagnosis: Finding indolent cancers that may not cause harm.